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Background: Tuberculosis (TB) is generally well controlled in Malaysia, but remains an important problem in the
nation’s eastern states. In order to better understand factors contributing to high TB rates in the eastern state of
Sabah, our aims were to describe characteristics of patients with TB at a large outpatient clinic, and determine the
prevalence of HIV co-infection. Additionally, we sought to test sensitivity and specificity of the locally-available
point-of-care HIV test kits.
Methods: We enrolled consenting adults with smear-positive pulmonary TB for a 2-year period at Luyang Clinic,
Kota Kinabalu, Malaysia. Participants were questioned about ethnicity, smoking, prior TB, disease duration, symptoms
and comorbidities. Chest radiographs were scored using a previously devised tool. HIV was tested after counselling
using 2 point-of-care tests for each patient: the test routinely in use at the TB clinic (either Advanced Quality™ Rapid
Anti-HIV 1&2, FACTS anti-HIV 1/2 RAPID or HIV (1 + 2) Antibody Colloidal Gold), and a comparator test (Abbott
Determine™ HIV-1/2, Inverness Medical). Positive tests were confirmed by enzyme immunoassay (EIA), particle
agglutination and line immunoassay.
Results: 176 participants were enrolled; 59 (33.5%) were non-Malaysians and 104 (59.1%) were male. Smoking
rates were high (81/104 males, 77.9%), most had cavitary disease (51/145, 64.8%), and 81/176 (46.0%) had haemoptysis.
The median period of symptoms prior to treatment onset was 8 weeks. Diabetes was present in 12. People with diabetes
or other comorbidities had less severe TB, suggesting different healthcare seeking behaviours in this group. All
participants consented to HIV testing: three (1.7%) were positive according to Determine™ and EIA, but one of
these tested negative on the point-of-care test available at the clinic (Advanced Quality™ Rapid Anti-HIV 1&2). The
low number of positive tests and changes in locally-available test type meant that accurate estimates of sensitivity
and specificity were not possible.
Conclusion: Patients had advanced disease at diagnosis, long diagnostic delays, low HIV co-infection rates, high
smoking rates among males, and migrants may be over-represented. These findings provide important insights to
guide local TB control efforts. Caution is required in using some point-of-care HIV tests, and ongoing quality control
measures are of major importance.* Correspondence: anna.ralph@menzies.edu.au
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Tuberculosis (TB) is a disease of major public health sig-
nificance in Malaysia, with a current estimated incidence
of 80 new cases annually per 100,000 population [1].
While important successes have been achieved in TB
control nationwide [1,2], TB control has proven to be
more challenging in Malaysian Borneo. The state of
Sabah in eastern Malaysia on the island of Borneo
contains approximately 10% of the country’s total popu-
lation, but a disproportionally high burden of the coun-
try’s TB cases, estimated at 20-30% [3,4]. The case
notification rate for Sabah has been sustained at higher
levels of 144 to 217 per 100,000 population during re-
cent decades while rates have fallen in other parts of
Malaysia [5].
Reasons for the greater difficulty in achieving TB con-
trol in Sabah are unclear. The extent to which the local
epidemic might be driven by HIV, migration from re-
gional high-burden settings, drug resistance, delayed
diagnosis, high smoking rates, diabetes or other factors,
has not been clearly elucidated. Our own data indicate
that drug resistance in the outpatient setting is uncom-
mon (publication pending); this is supported by data
from the local laboratory [4]. Nations which are close
neighbours of Sabah have higher reported TB incidence
than Malaysia (Philippines: 265/100,000; Indonesia 185/
100,000 [1]), but the extent to which immigrants con-
tribute to local TB case notifications is unclear. Migrants
are thought to comprise approximately 27.8% of the
Sabah population [6]. Regarding HIV as a contributor to
TB rates, the rate of HIV co-infection in people with TB
appears relatively low by international standards for
Malaysia as a whole at 6.1% [1], with HIV status estab-
lished in a high proportion of TB patients (97%) [1].
Rates of HIV among TB patients have not been pub-
lished from Eastern Malaysia, but were found to be 7.7%
in a 2012 study of 530 people in Western Malaysian hos-
pitals [7]. Our unpublished data from the largest hospital
in Sabah show an average of 63 new diagnoses of TB-
HIV co-infection and 15 deaths annually between 2010
and 2013. Therefore although we recognise TB-HIV co-
infection as a serious problem in the hospital setting, ac-
curate data on TB-HIV co-infection in Sabah are lacking.
HIV point-of-care (POC) blood tests have been an es-
sential and cost-effective component of HIV care in out-
patient clinics, especially in resource-limited settings [8]
but increasingly also in higher income settings [9]. A
large number of manufacturers provide low-cost HIV
POC tests. Such tests usually have reported sensitivity
of >95% and specificity >99% under laboratory condi-
tions [10]. The World Health Organisation (WHO) rec-
ommends a minimum HIV test sensitivity of 99% and
specificity of 98% [11]. Problems with POC tests can exist
however, including inadequate sensitivity [12], inadequatespecificity [13,14] and faulty batches [15]. The simplicity
of the tests also can provide a false sense of assur-
ance about requirements for quality control measures
and staff training. Lowest-cost tests can be especially
appealing to budget-conscious decision makers but may
underperform.
In order to better understand the factors contributing
to high ongoing TB rates in Sabah, our aims were to de-
termine epidemiological characteristics and HIV status
of patients with tuberculosis at a large outpatient clinic
in Kota Kinabalu Sabah. Additionally, we sought to test
the sensitivity and specificity of the HIV POC test kit
stocked by the TB clinic against another used-widely
POC test. In the absence of readily-available onsite myco-
bacterial culture, we restricted the study to smear-positive
pulmonary TB patients is order to include only those most
likely to have true TB.
Methods
Setting
We enrolled participants at the Luyang Tuberculosis
Outpatient Clinic, Kota Kinabalu, Malaysia, from July 4th
2012 until July 3rd 2014. This is the largest TB clinic in
Kota Kinabalu treating almost 200 patients annually. It
offers smear microscopy, directly observed therapy for
TB, and receives referrals of suspected or confirmed TB
cases from other Kota Kinabalu practitioners. Kota
Kinabalu has a population of approximately 452,940 [6].
Participants and procedures
Participants were eligible if they had smear-positive pul-
monary TB, were aged ≥15 years, and provided written
informed consent. They were asked about their ethnicity;
smoking status including number of cigarettes per day
and among ex-smokers, when they had quit; prior TB;
disease duration and symptoms; and comorbidities. Co-
morbidity data were based on patient report rather than
active screening. Ethnicity was determined by asking
people what ethnicity they identified as, in which coun-
try they were born, and their current address. Ethnicity
alone does not clearly define nationality due to the rep-
resentation of the same ethnic groups (such as Bajau) in
both Malaysia and the Philippines, and because immi-
grants may state their ethnicity as being that of their
Malaysian spouse. TB care is provided free of charge to
non-citizens.
TB disease severity was assessed using maximum re-
corded smear microscopy grade (1+, 2+ or 3+), presence
of cavitary disease, and radiological score [16].
HIV pre-test counselling was provided both by the TB
clinic doctor responsible for diagnosing TB and com-
mencing treatment, and by the research nurse before
collecting a blood sample. HIV post-test counselling was
provided by the clinic doctor. Two HIV tests were
Table 1 Study participant characteristics
Characteristic Number
Number 176
Age in years: median (range) 30 (15–73)
Male: no. (%) 104 (59.1%)
Nationality: no. (%)
Malaysian 117 (66.5%)*
Indigenous 106 (60.2%)
Chinese 10 (5.7%)
Indian 1 (0.6%)
Filipino 53 (30.1%)
Indonesian 6 (3.4%)
Co-morbidities: no. (%)
Diabetes 12 (6.8%)
Hypertension 9 (5.1%)
Asthma 6 (3.4%)
HIV 3 (1.7%)
Hepatitis B 2 (1.1%)
Chronic renal disease 1 (0.6%)
Cardiovascular disease 1 (0.6%)
Smoking status:
Current smoker 40 (22.7%)
Ex-smoker 50 (28.4%)
Non-smoker 86 (48.9%)
When smoking ceased: median no. months ago (IQR) 3.5 (2–24)
Past TB 13 (7.4%)
Radiological severity:
Cavitary disease 51/145 (64.8%)
Score: mean (standard deviation) 69.4 (34.9)
Smear grade: no. (%)
Scanty 27 (17.0%)
1+ 46 (28.9%)
2+ 40 (25.2%)
3+ 46 (28.9%)
BMI (kg/m2): mean (range)† 18.1 (10.0-31.1)
Haemoptysis: no. (%) 81 (46.0%)
Reported symptom duration in weeks:
median (range)†
8 (1–52)
*Percentages may not add up to 100 due to rounding.
†n = 174, data missing for 2 individuals.
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locally-available POC blood test provided for routine use
at the clinic, and a comparator POC blood test provided
by the study. The clinic-provided test types included:
‘Advanced Quality™ Rapid Anti-HIV 1&2’ (InTec Products,
Inc, Xiamen, China, reported sensitivity and specificity
100% [17]), ‘FACTS anti-HIV 1/2 RAPID’ (Scientifacts
Co Ltd, Malaysia, no reported sensitivity or specificity
available) and ‘HIV (1 + 2) Antibody Colloidal Gold’ (KHB
Shanghai Kehua Bioengineering Co PtyLtd, China, re-
ported sensitivity and specificity 100% [18]). The com-
parator study test throughout the study was Abbott
Determine™ HIV-1/2 (Inverness Medical, reported specifi-
city 99.6%, sensitivity 99.4% [19]). Test kits were stored in
air conditioned laboratory when not in use. New positive
tests were confirmed by enzyme immunoassay (EIA), par-
ticle agglutination (PA) and line immunoassay (LIA) per-
formed at Queen Elizabeth Hospital laboratory.
Ethics
Ethical approval was obtained from the Medical Research
Sub-Committee, Malaysian Ministry of Health (NMRR-
11-1051-10491) and the Human Research Ethics Com-
mittee of Menzies School of Health Research, Australia
(2010–1398).
Statistics
Data were analysed using Stata™ 13.1. (Stata Corp,
College Station, Texas, USA). Continuous variables were
compared using Student’s T test or Wilcoxon Rank Sum
test. Log transformation was applied to log-normal data
(illness duration). Categorical variables were compared
using Chi-squared or Fisher’s Exact test, as appropriate.
Associations between patient characteristics and TB
disease severity measures were tested using multivari-
able linear or logistic regression models. Logistic re-
gression models were used to calculate odds ratios (OR)
for associations between comorbidities and body mass
index (BMI).
Results
During the 2-year study period from July 4th 2012 to July
3rd 2014, 176 consenting participants were enrolled out
of 395 people referred. 79 were ineligible, 12 were con-
sidered unsuitable by the research staff (e.g. too unwell
or pregnant) and 128 did not consent. Chest x-rays were
available for review in 145 people.
Demographics
Patient characteristics are shown in Table 1. Males were
over-represented, and one third of patients (33.5%) were
migrants. The geographical distribution of TB cases as
determined from participants’ addresses is in shown
in Figure 1. Some apparent hotspots appeared evidentincluding Pulau Gaya, a migrant community off-shore
island with an estimated population of 6000, connected to
Kota Kinabalu via a ferry service.
Participant characteristics and comorbidities
Patients had advanced disease at diagnosis on the
whole, on the basis of low mean BMI, proportion with
Figure 1 Map of Kota Kinabalu demonstrating the geographical distribution of cases enrolled in the study. Circles represent the
proportional number of cases in each subdistrict, according to home address details provided by study participants.
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Males tended to have more severe disease than females
(Figure 2A and B). No statistically significant associations
were found between ethnicity and TB severity, although
slightly more people of non-Malaysian ethnicity had
cavitary disease, 36/51 (70.6%) versus 58/94 (61.7%) in
Malaysians (p = 0.285).
Regarding diagnostic delays, the median reported dur-
ation of symptoms prior to starting treatment was 8 weeks.Longer illness durations were observed in people with
cavitary disease, high smear grade, and in the 6 individ-
uals from Indonesia, but the latter was not statistically
significant. Comparing geometric means of illness dur-
ation, these were: cavitary disease - 7.5 weeks, com-
pared with 5.7 weeks in non-cavitary disease, p = 0.038;
3+ smear grade - 8.0 weeks, compared with 5.8 weeks
in those <3+, p = 0.020; Indonesians - 10.3 weeks, com-
pared with 6.1 weeks in Malaysians, p = 0.123. Illness
Figure 2 Severity of pulmonary tuberculosis according to sex and presence or absence of non-HIV comorbidities. A. Sputum microscopy
grade in males and females. B. Baseline chest x-ray score in males and females. C. Baseline chest x-ray score in the presence and absence of
recognised co-morbidities. Chest x-rays were available in 145 people. Any comorbidity included diabetes, asthma, hypertension, hepatitis B, chronic
renal disease, cardiovascular disease, gastrointestinal disorder or chronic back pain. Box plots show 50th centile (line), 25th and 75th centiles (box)
and minimum and maximum values (whiskers).
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ence of haemoptysis.
More than half the participants were current or ex-
smokers. Nine females (12.5%) had ever smoked, versus
81 males (77.9%), p < 0.001. Among ex-smokers, the
median time of cessation was 3.5 months prior to com-
mencement of TB treatment.
Diabetes was the most commonly reported comorbid-
ity, followed by hypertension and asthma (Table 1).
Hepatitis B virus positivity, not routinely tested during
most of the study, was recorded in 2 individuals. As ex-
pected, diabetes and hypertension were significantly as-
sociated with BMI and age (p ≤ 0.004 in each instance)
Even controlling for BMI, the presence of diabetes,
asthma or ‘any comorbidity’ (diabetes, asthma, hyperten-
sion, hepatitis B, chronic renal disease, cardiovascular
disease, gastrointestinal disorder or chronic back painbut excluding HIV) was associated with less severe TB
on X-ray (Figure 2C).
HIV results
All participants consented to HIV testing. The HIV POC
test stocked by the clinic changed regularly during the
study period, with occasional stock-out periods, and also
two instances in which Determine™ was unavailable
(Table 2). Of the 176 participants analysed, 3 (1.7%) were
HIV positive on Determine™ HIV-1/2 test (Table 2). Two
were new diagnoses, both confirmed positive on EIA, PA
and LIA. The third was a known pre-existing diagnosis.
The locally-available test available in two instances (‘Ad-
vanced Quality™ Rapid Anti-HIV 1&2’) was positive in
one participant but negative in the other. Although
numbers were too small for definitive assessment, com-
pared with Determine™, this provided a sensitivity of
Table 2 HIV test results among smear-positive pulmonary TB patients, Luyang Clinic, 2012-14
Determine™ result TOTAL
Positive Negative Not available
FACTS anti-HIV 1/2 RAPID (Scientifacts Co Ltd, Malaysia) 0 15 0
Advanced Quality™ Rapid Anti-HIV 1&2, (InTec Products, Inc, Xiamen, China) 2 95 2
HIV (1 + 2) Antibody Colloidal Gold (KHB Shanghai Kehua Bioengineering Co PtyLtd, China 1 31 0
Not available 0 30 0
TOTAL 3 171 2 176
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Rapid Anti-HIV 1&2’, in contrast with the information
provided in the package insert [17]. The locally-available
test used in the third instance (‘HIV (1 + 2) Antibody
Colloidal Gold’) gave a positive result. Clinical summar-
ies of the TB-HIV co-infected individuals are provided in
Table 3. One died 4 months after the TB diagnosis, at-
tributed to presumptive cerebral toxoplasmosis, with a
differential diagnosis of cerebral tuberculoma.
Discussion
We have found that TB patients in Kota Kinabalu have
advanced disease at diagnosis, long diagnostic delays, low
HIV co-infection rates, high smoking rates among males,
and that migrants may be over-represented. These findings
provide important insights to guide local TB control ef-
forts. Although Malaysia is an upper middle-income coun-
try which has achieved impressive TB control at a national
level, our study participants had severity measures similar
to or worse than we have previously found in comparable
patients in a low-resource Asian setting [20]. Forty six per-
cent of participants in the current analysis had haemopty-
sis, nearly a third had a microscopy grade of 3+, and two
thirds had cavitary disease. Although recall bias may influ-
ence people’s reported symptom duration, the median re-
ported diagnostic delay of 8 weeks is 4 weeks longer than
has been reported on average from elsewhere [21,22], and
was associated with worse disease.
The presence of advanced disease suggests that earlier
detection of pulmonary TB must become a priority forTable 3 Characteristics and outcomes of study participants w
Study participant New HIV diagnosis made
at time of TB diagnosis
CD4 T cell co
cell/μL
57 year old Indigenous
Malaysian male
Yes 328
22 year old Filipino female No (diagnosed 1 year prior) 123
19 year old Indigenous
Malaysian male
Yes 1local healthcare services. This could be achieved through
active case detection efforts, improved contact tracing,
and a lower clinical threshold for considering TB, espe-
cially targeted at apparent geographical hotspots or at-
risk communities. Mathematical modelling has indicated
that control efforts targeting TB hotspots can be an effi-
cient strategy to reduce wider TB rates [23]. Improved
TB control among the migrant population group would
have major individual and public health benefits, and
impact favourably on Malaysian national TB statistics.
Other Malaysian studies have estimated the proportion
of cases occurring in migrants as being substantially
fewer, at 10% in a 2004 study [2] and 17% in a study
from 2000–2007 [24]. It makes sense that as TB control
in Malaysia continues to improve, an increasing proportion
of total TB cases will occur in people from neighbouring
high-burden settings. In Australia for example, >85% of all
TB cases now occur in migrants or visitors from high-
burden countries [25].
Implementation of public policy to reduce smoking
rates is greatly needed. Smoking increases the risk of TB
infection and disease [26,27]. In this study, 51.1% of par-
ticipants were current or ex-smokers, with many of the
ex-smokers having quit only since the onset of respira-
tory symptoms. By comparison, in a recent study from
Mexico, 24.4% of pulmonary TB patients were current
smokers or smokers within the last 12 months [27]. Pol-
icy changes such as increased cigarette prices [28] are
needed in Malaysia and other Asian nations in which
smoking consumption rates remain very high amongith TB-HIV co-infection
unt: Clinical details
Commenced on AZT, 3TC and efavirenz. TB cured.
Migrant not eligible for free HIV treatment who had previously
defaulted from antiretroviral therapy; remains under follow up
with a view to re-start antiretrovirals if possible.
Attended HIV clinic for baseline assessment but did not return
for results or commencement of treatment. Died in hospital with
cerebral mass lesion 4 months after TB-HIV diagnosis, attributed
to presumptive cerebral toxoplasmosis, with a differential diagnosis
of cerebral tuberculoma.
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that some patients had quit smoking due to pulmonary
irritability (i.e. cough), sometimes at a date slightly
before the time that they recalled the onset of TB
symptoms. This raises the question of whether smok-
ing cessation due to respiratory symptoms could be
an early sign of tuberculosis in a high-burden setting,
and hence whether smoking cessation due to increasing
respiratory symptoms should prompt investigation for
pulmonary TB.
Our data indicate that caution is required in the use of
low-cost point-of-care HIV tests, which should be care-
fully evaluated before they become adopted as national
standard of care. The low number of HIV positive re-
sults meant that test characteristics could not be ascer-
tained with confidence. However, one instance of HIV
positivity according to Determine™/EIA was negative on
the clinic-provided test, raising major concerns. We had
intended to test the sensitivity and specificity of one
POC against Determine™ but the test stocked by the
clinic changed throughout the study period, depending
on clinic purchasing patterns which we could not influ-
ence. Our experience with low-cost rapid tests in clinical
practice in Kota Kinabalu has included other instances of
inadequate sensitivity, including in antenatal screening. We
therefore recommend discontinuation of use of low-
performing tests. A limitation of this study was that we did
not use a gold standard comparator HIV test, although
positive results were cross-checked with methods consid-
ered as gold standards. A study in Uganda has identified
problems with low specificity (false positive results) with
the Determine™ rapid tests [14], which we did not observe.
One reason for lower performance of POC tests in field
settings compared with manufacturer-provided laboratory
data may be the temperature at which tests are often
stored and used. Routine practice at our study site was for
the clinic’s test kits belonging to be kept in the general clin-
ical area which is not air conditioned, where the ambient
temperature is often ≥25°C. A transition away from the
traditional testing location of the laboratory to point-of-
care testing in the clinic must be accompanied by training
of clinical staff in the principles of laboratory quality con-
trol procedures.
It is welcome news that high ascertainment of HIV
status was achieved, and that the prevalence of HIV co-
infection among smear-positive TB patients in the out-
patient setting was low at 1.7%. Comparison can be
drawn with nearby eastern Indonesia (Papua Province),
where the HIV rate among TB smear-positive outpa-
tients is 13% [30]. However, one TB-HIV co-infected pa-
tient died, and barriers to institution of antiretroviral
treatment were faced in another. Barriers are well de-
scribed regionally [30] and globally [31]. Despite the re-
assuringly low community HIV rate we found, our clinicalexperience in the hospital setting in Kota Kinabalu is, con-
trastingly, of a major and rising problem with HIV and TB-
HIV co-infection. Unpublished 2013 data from our Queen
Elizabeth Hospital clinic, the main referral centre for HIV
management in Kota Kinabalu, show 253 new HIV diagno-
ses. Seventy seven had TB co-infection, and 12 died in
2013. Thus there is no scope for complacency.
Limitations of this study are that participants may not
be representative of Malaysian Borneo TB patients as a
whole. Males were over-represented, but male over-
representation among PTB patients is not uncommon in
Asia [32], for a variety of reasons reviewed elsewhere
[33]. Our selection criteria (smear-positive outpatients)
would have selected for a group less likely to have HIV.
Reluctance to have an HIV test was not cited as a reason
for non-consent – people not enrolled in the study also
had HIV testing performed as part of routine clinical
care. Non-HIV co-morbidity data were based on patient
report only; hence co-morbidities were likely to be
under-estimated. Determination of true ethnicity can be
hampered by a reluctance to admit to non-local status,
partly related to fears about health care costs for non-
residents, or deportation; we reassured people that TB
treatment is free regardless of ethnicity, and ethnicity
would remain confidential; also, we did not rely on
stated ethnicity alone, as described in the Methods.
A somewhat unexpected finding was that people with
co-morbidities had less-severe disease. This might be be-
cause people knowledgeable of their co-morbidities may
be those more likely to seek health care earlier, and to
be engaged in health care services. Just as TB is an im-
portant opportunity to detect HIV, so too is it an im-
portant opportunity to detect diabetes. Screening for
diabetes could be an important additional strategy to
add to TB care in Kota Kinabalu, particularly in older in-
dividuals with higher BMI. The finding of more ad-
vanced disease in males might also have been related to
their health-seeking behaviour; alternatively their high
smoking rates may have contributed, although we could
not find a statistically significant association between
smoking and severity per se.
Conclusions
In summary, the low rates of TB-HIV co-infection we
identified provide optimism for local TB control. We
recommend that careful quality control procedures be
applied to HIV point-of-care testing, and that purchas-
ing of test kits be guided by evidence of adequate test
characteristics in keeping with WHO recommendations.
Our findings have prompted changed local practices re-
garding HIV test kit use, and improved communication
between the TB and HIV clinics. We suggest that a cost
effective strategy for controlling local TB rates would be
a greater focus on geographical TB foci comprising
William et al. BMC Infectious Diseases  (2015) 15:32 Page 8 of 9socioeconomically disadvantaged migrant populations in
Sabah. Since TB rates in eastern Malaysia have a dispro-
portionate influence on national rates, successes in
Sabah could translate into a fall in national TB rates.
Local operational research in strengthening TB control
is required.
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